stomach cancer (Cancer)
Information
- Disease name
- stomach cancer
- Disease ID
- DOID:10534
- Description
- "A gastrointestinal system cancer that is located_in the stomach." [url:http\://cancergenome.nih.gov/cancersselected/stomach-esophagealcancer, url:http\://en.wikipedia.org/wiki/Stomach]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| TP53 | 17 | 7,668,421 | 7,687,490 | 30 |
| APC | 5 | 112,737,885 | 112,846,239 | 6 |
| PIK3CA | 3 | 179,148,357 | 179,240,093 | 6 |
| KIT | 4 | 54,657,913 | 54,740,770 | 6 |
| CTNNB1 | 3 | 41,220,551 | 41,239,888 | 4 |
| KRAS | 12 | 25,205,246 | 25,250,929 | 4 |
| RET | 10 | 43,077,069 | 43,130,351 | 4 |
| ERBB4 | 2 | 211,375,717 | 212,538,802 | 4 |
| STK11 | 19 | 1,205,778 | 1,228,431 | 4 |
| HRAS | 11 | 532,243 | 535,550 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03488667 | Active, not recruiting | Phase 2 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | June 27, 2018 | April 30, 2025 |
| NCT05931445 | Active, not recruiting | N/A | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | January 26, 2021 | March 31, 2027 |
| NCT03760822 | Active, not recruiting | Phase 2 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | November 16, 2018 | September 2024 |
| NCT05311176 | Active, not recruiting | Phase 2 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) | August 17, 2022 | July 1, 2026 |
| NCT00296322 | Completed | Phase 3 | Trial of Adjuvant Chemotherapy for Gastric Cancer | October 2001 | March 2010 |
| NCT00296335 | Completed | Phase 3 | Trial of Adjuvant Chemotherapy for Gastric Cancer | February 2002 | December 2009 |
| NCT00342004 | Completed | A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among Women | May 1, 1997 | July 28, 2020 | |
| NCT00201747 | Completed | Phase 2 | Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer | September 2001 | February 2010 |
| NCT00374036 | Completed | Phase 3 | Metastatic Gastric Cancer FFCD 03-07 | June 2005 | December 2009 |
| NCT00394433 | Completed | Phase 2 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | September 2006 | October 2016 |
| NCT00446290 | Completed | Phase 1 | Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer | March 2006 | October 2007 |
| NCT00525785 | Completed | Phase 2 | Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | January 2004 | January 2016 |
| NCT00780494 | Completed | Phase 2 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | February 2009 | December 31, 2017 |
| NCT06161233 | Completed | N/A | Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy | May 16, 2023 | January 31, 2024 |
| NCT00857246 | Completed | Phase 2 | Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | July 2005 | October 2015 |
| NCT00858338 | Completed | Phase 2 | Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | December 2002 | February 2012 |
| NCT00911820 | Completed | Phase 2 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | July 2009 | August 2013 |
| NCT05638048 | Completed | N/A | Effect of Precise Grip Strength Training on PICC Catheter-Related Thrombosis in Cancer Patients | July 10, 2022 | January 10, 2023 |
| NCT01016639 | Completed | Phase 1/Phase 2 | Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer | June 2003 | July 2009 |
| NCT05336058 | Completed | Development of Free DNA Multi-target Methylated PCR for Auxiliary Diagnosis of Gastric Cancer | February 1, 2022 | February 4, 2024 | |
| NCT00215462 | Completed | Phase 2 | Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma | June 2000 | August 2005 |
| NCT01236053 | Completed | Cancer in Patients With Gabapentin (GPRD) | June 2010 | September 2010 | |
| NCT01246960 | Completed | Phase 2 | A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer | April 2011 | May 2014 |
| NCT01257711 | Completed | N/A | A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer | October 9, 2008 | February 12, 2020 |
| NCT04797624 | Completed | Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients? | January 15, 2021 | February 15, 2021 | |
| NCT04770623 | Completed | Phase 2 | Docetaxel and Irinotecan in Gastric Cancer | March 5, 2021 | January 9, 2023 |
| NCT03937440 | Completed | N/A | The Effect of Deep Neuromuscular Block on the Perioperative Stress Response Reduction and Postoperative Recovery Enhancement in Robot-assisted Stomach Cancer Surgery | July 3, 2019 | December 15, 2019 |
| NCT01659619 | Completed | Phase 2 | Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis | April 2012 | October 2012 |
| NCT01760070 | Completed | N/A | Comparison of O-type Hybrid Knife and IT Knife in ESD | December 2012 | December 2014 |
| NCT02661971 | Completed | Phase 2/Phase 3 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | June 2016 | June 20, 2022 |
| NCT03076567 | Completed | Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer | March 9, 2017 | February 21, 2020 | |
| NCT00215514 | Completed | Early Phase 1 | Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma | September 2000 | July 2014 |
| NCT00291473 | Completed | Phase 1 | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers | July 2005 | August 2008 |
| NCT02604979 | Completed | The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study | September 23, 2015 | February 6, 2016 | |
| NCT02689284 | Completed | Phase 1/Phase 2 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | January 2016 | January 2021 |
| NCT02055313 | Completed | Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival | May 2012 | December 2020 | |
| NCT03662204 | Completed | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | August 23, 2018 | March 31, 2022 | |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT03604653 | Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | May 15, 2018 | May 1, 2021 | |
| NCT03515356 | Completed | N/A | Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy | June 13, 2018 | June 24, 2019 |
| NCT03384511 | Completed | Phase 4 | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | September 30, 2016 | January 28, 2018 |
| NCT02489422 | Completed | N/A | Programs To Support You During Chemotherapy | August 2016 | January 2020 |
| NCT02547064 | Completed | N/A | Effect of Modified Stylet Angulation on the Intubation With GlideScope® | October 2015 | January 2016 |
| NCT02581462 | Completed | Phase 2/Phase 3 | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer | June 2016 | July 17, 2020 |
| NCT06263088 | Not yet recruiting | N/A | EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | July 2024 | June 30, 2026 |
| NCT06277908 | Not yet recruiting | Postoperative Morbidity and Mortality After Gastric Cancer Surgery | March 18, 2024 | December 31, 2024 | |
| NCT06447064 | Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) | April 29, 2024 | March 31, 2027 | |
| NCT01048281 | Recruiting | Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma | August 2002 | January 2099 | |
| NCT03027427 | Recruiting | Prospective Evaluation and Molecular Profiling in People With Gastric Tumors | February 1, 2017 | December 31, 2030 | |
| NCT03030404 | Recruiting | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | January 27, 2017 | December 31, 2030 | |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04135781 | Recruiting | Phase 3 | Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | March 1, 2020 | October 31, 2024 |
| NCT04308837 | Recruiting | Phase 2 | A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation | December 3, 2018 | August 2025 |
| NCT04426669 | Recruiting | Phase 1/Phase 2 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | May 15, 2020 | January 2024 |
| NCT04484636 | Recruiting | N/A | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) | October 28, 2020 | July 30, 2024 |
| NCT04526470 | Recruiting | Phase 1/Phase 2 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | September 1, 2020 | December 2024 |
| NCT04819971 | Recruiting | Phase 2 | Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC | December 1, 2021 | December 31, 2025 |
| NCT04825834 | Recruiting | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) | March 22, 2021 | May 31, 2026 | |
| NCT04890171 | Recruiting | N/A | Comparison of Endoscopic Resection and Surgery for Early Gastric Cancer With Undifferentiated Histological Type | June 11, 2021 | December 31, 2027 |
| NCT04907643 | Recruiting | N/A | Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | October 5, 2021 | March 2026 |
| NCT05187182 | Recruiting | Phase 1 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | June 2, 2023 | June 30, 2027 |
| NCT05238584 | Recruiting | N/A | Total Versus Partial Omentectomy in the Treatment of Gastric Cancer | January 1, 2022 | July 1, 2024 |
| NCT05366881 | Recruiting | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | May 3, 2022 | December 2026 | |
| NCT05396300 | Recruiting | Phase 1 | A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | May 25, 2022 | May 15, 2025 |
| NCT05415475 | Recruiting | Phase 1 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | September 10, 2021 | September 15, 2025 |
| NCT05426135 | Recruiting | Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment | June 1, 2022 | October 2026 | |
| NCT05427383 | Recruiting | Phase 2/Phase 3 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | April 7, 2022 | November 2026 |
| NCT05489250 | Recruiting | The PLATON Network | October 28, 2020 | May 31, 2032 | |
| NCT05494060 | Recruiting | Phase 2 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma | March 16, 2022 | February 2027 |
| NCT05697198 | Recruiting | PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine | April 19, 2021 | September 2024 | |
| NCT06028737 | Recruiting | Phase 2/Phase 3 | Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | August 25, 2023 | December 2031 |
| NCT06199895 | Recruiting | Phase 2 | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer | November 28, 2023 | November 2025 |
| NCT00511576 | Terminated | Phase 1 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | August 2007 | March 2009 |
| NCT01774851 | Terminated | Phase 2 | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | January 2013 | December 2015 |
| NCT00359476 | Terminated | Phase 2/Phase 3 | A Study of Vinflunine in Patients With Gastric Cancer | March 2007 | November 2007 |
| NCT01445327 | Terminated | Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers | February 20, 2007 | May 22, 2014 | |
| NCT02216149 | Terminated | Phase 2 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow | January 2015 | August 2018 |
| NCT01010334 | Terminated | N/A | Comparison of Standard of Care or Treatment on Protocol | March 2009 | July 2011 |
| NCT02113683 | Terminated | Validation of MMS Test for Cancer Monitoring | May 2014 | June 20, 2018 | |
| NCT02191566 | Terminated | Phase 2 | S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy | May 2015 | October 2019 |
| NCT03057171 | Unknown status | A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA | May 2015 | April 2020 | |
| NCT02699047 | Unknown status | N/A | Fish Oil Supplementation in Gastrointestinal Cancer | March 2015 | July 2017 |
| NCT03086291 | Unknown status | Phase 1 | A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy | January 4, 2018 | December 2020 |
| NCT03139487 | Unknown status | Phase 2 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism | August 7, 2017 | September 30, 2021 |
| NCT02325323 | Unknown status | Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia | May 2014 | June 2015 | |
| NCT03448835 | Unknown status | Phase 2 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | March 7, 2018 | January 1, 2022 |
| NCT02209415 | Unknown status | N/A | EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer | April 2011 | August 2016 |
| NCT04410887 | Unknown status | Phase 1/Phase 2 | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | December 2020 | March 2022 |
| NCT01179750 | Unknown status | Phase 3 | The Use of Ultrasonic Coagulating Shears Compared to Monopolar Electrocautery in Open Gastric Cancer Surgery | January 2010 | June 2011 |
| NCT01038154 | Unknown status | Phase 4 | Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer | November 2009 | November 2012 |
| NCT04486651 | Unknown status | Phase 3 | HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer | September 16, 2020 | August 10, 2023 |
| NCT04493125 | Unknown status | N/A | The Effect of Mosapride Citrate on Gastrointestinal Motility After Gastrectomy: Prospective, Double Blind Placebo-controlled Study | July 27, 2020 | September 30, 2021 |
| NCT01319084 | Unknown status | Development of a Versatile Intra-operative On-screen Audiovisual Mentoring System Using TileproTM Program for Robotic Gastrectomy | March 2011 | February 2012 | |
| NCT04819958 | Unknown status | The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer | March 31, 2021 | August 30, 2021 | |
| NCT00948337 | Unknown status | Phase 2 | A Study With Health Educational Material on Health Promotion in Cancer Survivors | August 2009 | December 2010 |
| NCT01618474 | Unknown status | Phase 2 | Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients | May 2012 | December 2016 |
| NCT04001569 | Unknown status | Phase 1/Phase 2 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | May 14, 2019 | December 31, 2022 |
| NCT04014478 | Unknown status | N/A | A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain | July 15, 2019 | July 15, 2021 |
| NCT04215861 | Unknown status | Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy | October 1, 2019 | October 2021 | |
| NCT02943603 | Withdrawn | Phase 2 | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | January 2017 | July 2019 |
| NCT05471401 | Withdrawn | N/A | GI Organ Tracking Via Balloon Applicators | April 25, 2023 | May 31, 2025 |
| NCT00800969 | Withdrawn | Phase 2 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach | October 2008 | |
| NCT03644459 | Withdrawn | Phase 1 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | April 3, 2019 | August 2020 |
| NCT02205463 | Withdrawn | Phase 1 | KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer | December 2014 | July 2017 |
| NCT03704077 | Withdrawn | Phase 2 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | October 31, 2019 | September 30, 2024 |
| NCT00622804 | Withdrawn | Phase 3 | Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy | July 2007 |
- Disase is a (Disease Ontology)
- DOID:3119
- Cross Reference ID (Disease Ontology)
- GARD:7704
- Cross Reference ID (Disease Ontology)
- ICD10CM:C16
- Cross Reference ID (Disease Ontology)
- ICD10CM:C16.2
- Cross Reference ID (Disease Ontology)
- ICD10CM:C16.5
- Cross Reference ID (Disease Ontology)
- ICD10CM:C16.6
- Cross Reference ID (Disease Ontology)
- ICD9CM:151
- Cross Reference ID (Disease Ontology)
- ICD9CM:151.4
- Cross Reference ID (Disease Ontology)
- ICD9CM:151.5
- Cross Reference ID (Disease Ontology)
- ICD9CM:151.6
- Cross Reference ID (Disease Ontology)
- MESH:D013274
- Cross Reference ID (Disease Ontology)
- MIM:613659
- Cross Reference ID (Disease Ontology)
- NCI:C3387
- Cross Reference ID (Disease Ontology)
- NCI:C9331
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:126824007
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269459004
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269460009
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:93717002
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:94074003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0024623
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0038356
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153421
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153422
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0153423
- Exact Synonym (Disease Ontology)
- gastric cancer
- Exact Synonym (Disease Ontology)
- gastric neoplasm
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012126